SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

NEW YORK, Jan 7, 2026, 11:26 (EST) — Regular session

  • SoFi shares down about 1.4% mid-morning, lagging the broader market
  • Filing shows underwriters exercised option tied to December stock offering; total shares sold rose to 57.75 million
  • BofA restarted coverage at underperform, pointing to valuation and limited upside

SoFi Technologies shares were down about 1.4% at $26.61 by 11:26 a.m. EST on Wednesday, extending recent weakness as investors absorbed fresh details on stock sold into the market.

A regulatory filing showed the underwriters of SoFi’s December share sale exercised their option to buy additional stock, and the company completed that extra issuance on Jan. 5. The “greenshoe” option — a standard clause that lets banks buy more shares — pushed total shares sold in the offering to 57,754,660 at $27.50 each, with Goldman Sachs, BofA Securities, Citigroup, Deutsche Bank and Mizuho listed as underwriters. CloudFront

The added stock matters now because it lifts the number of shares in the market, diluting existing holders and often capping near-term gains as investors wait for demand to catch up with supply. Bank of America analyst Mihir Bhatia, restarting coverage with an underperform rating and a $20.50 price target, called the December capital raise a “modest positive” that gives SoFi “ammunition” to keep investing, but argued any acquisition is “likely to be smaller and more complementary than game changing.” TipRanks

SoFi’s drop came even as the broader tape was slightly higher, with the S&P 500 proxy SPY up about 0.1% and the tech-heavy QQQ up about 0.4%. Digital-lending peers were also lower, with Upstart down about 1.3% and LendingClub down about 1.6%.

Traders are treating the $27.50 offering price as a quick gut-check level. SoFi is now below it, which can keep sellers active if investors think more stock could surface from the deal’s after-effects.

The bigger question is what the company does with a thicker capital cushion. Investors have been looking for signs that SoFi will lean into lending growth, spend more to pull in deposits, or use the balance sheet for targeted deals, rather than chase a “big swing” transaction.

But the setup cuts both ways. If credit turns — particularly in unsecured consumer lending — losses can jump fast, and a market already sensitive to dilution could punish any hint that SoFi needs more capital or is taking on risk to keep growth running.

The next clear catalyst is SoFi’s fourth-quarter and full-year 2025 results, due Jan. 30 before the U.S. market opens, when investors will focus on loan growth, credit performance and any updated view on how the company plans to deploy capital. Sofi

Stock Market Today

  • Parabilis Medicines raises $305 million as CEO warms to an IPO
    January 8, 2026, 7:28 AM EST. Parabilis Medicines has raised $305 million in a new funding round, helping move its lead cancer drug candidate into late-stage testing. The round is a Series F, signaling the company has sought external capital at least six times while remaining private. CEO Mathai Mammen has signaled renewed interest in an IPO after previously saying there was no need to go public. The company, formerly FogPharma, is pursuing a corkscrew-shaped peptide approach intended to breach cells more effectively, including tumors. The capital supports advancing the program and sustaining the private development path that has defined the company since inception.
Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next
Previous Story

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders
Next Story

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

Go toTop